Zero Trust assessment in pharma depends on microsegmentation

At a glance

What this is: This is a practical guide to Zero Trust assessment for pharmaceutical and biotech environments, with microsegmentation positioned as the foundational control.

Why it matters: It matters because pharma and biotech teams must protect converged IT/OT estates, research data, and production systems without relying on perimeter trust or broad network access.

By the numbers:

• 86.5% of organizations have started implementing at least one Zero Trust pillar, reflecting the shift from concept to operational necessity.
• The 2024 Non-Human Identity Security Report found that 35.6% of organisations cite managing consistent access across hybrid and multi-cloud environments as their top NHI security challenge.

👉 Read Elisity's practical guide to Zero Trust assessment for pharmaceutical and biotech companies

Context

Zero Trust in pharmaceutical and biotech settings is fundamentally about removing implicit trust from environments where research, manufacturing, and clinical systems now share more infrastructure than most teams can safely tolerate. The primary issue is not a lack of security tooling, but a governance gap: flat networks, legacy devices, and mixed IT/OT estates still allow broad lateral movement.

For IAM practitioners, this also has an identity dimension. Microsegmentation is increasingly enforced through identity-based policy, so the quality of workload identity, device trust, and access lifecycle controls directly affects whether Zero Trust becomes a real operating model or just a network redesign exercise.

Key questions

Q: What breaks when microsegmentation is missing in industrial environments?

A: Without microsegmentation, a single compromised host or account can move across too much of the environment, including build systems, update services, and operational assets. That turns a localized breach into programme-wide disruption. The common failure is treating network design as simple connectivity management rather than as a control on what identities and workloads are allowed to reach.

Q: Why do converged industrial environments complicate Zero Trust Architecture?

A: Zero Trust assumes every access path can be continuously verified and constrained, but industrial environments often depend on legacy protocols, vendor maintenance paths, and devices that cannot support uniform controls. The result is a partial trust model that must be enforced through compensating segmentation, explicit policy, and tighter privileged access governance.

Q: How do security teams know if segmentation is actually reducing risk?

A: They should look for shrinking reachable paths between critical systems, fewer allowed communications over time, and clear ownership for exceptions. If the policy set only exists on paper, or if teams cannot prove that compromised systems are contained, the programme is not delivering meaningful risk reduction.

Q: Who should own Zero Trust decisions when IAM, networking, and cloud teams all touch the same controls?

A: IAM should own the access policy and lifecycle rules, while networking and cloud teams provide the enforcement points and telemetry. The accountability line matters because Zero Trust fails when no single team owns the end-to-end access decision.

Technical breakdown

Why microsegmentation is the control Zero Trust depends on

Microsegmentation breaks a network into smaller policy zones so communication is allowed only where explicitly authorised. In a pharma environment, that matters because laboratory devices, manufacturing systems, and corporate endpoints often share infrastructure but should not share trust. Unlike legacy VLAN-based segmentation, modern microsegmentation can express policy at application-to-application, user-to-application, or workload-to-workload level. That makes it far better suited to environments where systems move, scale, or change frequently. The architectural aim is simple: reduce the blast radius of compromise and prevent lateral movement from one exposed asset to the rest of the estate.

Practical implication: map critical communication paths before setting policy, or segmentation will be too coarse to stop spread.

Identity-based policy in converged IT and OT environments

The article’s strongest technical point is that segmentation rules should follow identity and context, not IP ranges alone. That matters in converged IT/OT environments because a device’s network location says little about its role, trust level, or business criticality. Identity-based policy can account for who or what is connecting, whether the endpoint is managed, and which application or process is trying to communicate. For pharmaceutical operations, that means security controls can be tuned to protect validated systems and production flows without forcing blanket isolation that breaks operations.

Practical implication: connect segmentation policy to asset identity and role so controls survive device movement and topology changes.

Zero Trust maturity needs measurable cross-functional governance

CISA’s maturity model is useful because it turns Zero Trust from a slogan into a staged operating model across identity, devices, networks, applications, and data. In pharma, the hard part is not naming the pillars but coordinating them across security, networking, OT, and application teams. Assessments fail when they focus only on technical coverage and ignore operating model readiness, validation constraints, and change control. A mature programme needs measurable policy coverage, clear ownership, and repeatable exception handling across regulated systems.

Practical implication: score maturity by enforcement coverage and operational ownership, not by whether a pilot has been started.

Threat narrative

Attacker objective: The attacker objective is to expand from one compromised asset into production, research, or clinical systems with enough reach to cause operational disruption or data loss.

1. Entry occurs when an attacker reaches a flat pharmaceutical network through a compromised endpoint, exposed remote access path, or weakly isolated third-party connection.
2. Escalation follows when the attacker uses the absence of segmentation to move from the initial foothold into lab, manufacturing, or clinical systems that should have been separated.
3. Impact occurs when the attacker disrupts production, delays critical drug delivery, or accesses sensitive research and patient data across the shared environment.

NHI Mgmt Group analysis

Microsegmentation is now a governance control, not just a network design choice. In regulated manufacturing environments, the question is no longer whether segmentation exists, but whether it is identity-aware enough to constrain trust between systems that must stay operational. Pharma teams that treat segmentation as an IT topology project will miss the real risk, which is uncontrolled blast radius across validated and business-critical assets. Practitioners should manage it as an access governance problem.

Blast-radius governance is the right named concept for pharma Zero Trust programmes. The article shows that the key measure is not the presence of a perimeter, but the size of the reachable environment after one system is compromised. That concept helps security leaders prioritise controls that reduce lateral movement across labs, plants, and office networks. The practical conclusion is to design around containment, not assumption of internal trust.

Pharmaceutical Zero Trust programmes fail when operating model readiness is ignored. The article correctly points to cross-functional alignment, because microsegmentation changes how security, networking, OT, and application teams share responsibility. Without ownership, change control, and exception handling, policy coverage becomes patchy and fragile. Teams should treat implementation as a governance programme with technical enforcement attached.

Identity-based segmentation creates an intersection point for IAM and network security teams. This is where NHI governance matters even in a mostly cyber_broad article, because workload identities, service credentials, and machine trust determine whether policy can be expressed accurately. If those identities are poorly governed, segmentation rules become brittle or overly permissive. Practitioners should align segmentation with identity lifecycle controls rather than leaving it as a standalone network project.

What this signals

Blast-radius governance: pharmaceutical teams should start measuring how far one compromised asset can reach, because that is the real Zero Trust maturity signal. If the reachable set remains broad, segmentation is still a design exercise rather than an enforcement control.

The identity angle is not optional where segmentation depends on workload and device trust. As environments become more converged, the quality of identity lifecycle controls, credential governance, and exception handling will determine whether policy remains accurate under change.

For teams using standards to anchor the programme, NIST SP 800-207 Zero Trust Architecture provides the architectural baseline, while NIST Cybersecurity Framework 2.0 helps translate maturity into operational governance.

For practitioners

• Inventory critical communication paths Map the exact application, device, and workload flows that support manufacturing, lab operations, and clinical systems before defining segmentation policy. Focus on where shared trust currently exists and where lateral movement would create the largest operational blast radius.
• Tie policy to identity, not subnet Use identity-aware controls so segmentation decisions follow systems and users as environments change. Avoid building the programme around static IP ranges that cannot reflect validated equipment, third-party access, or workload mobility.
• Start with high-value containment zones Prioritise the systems whose compromise would halt production or expose drug development data, then create narrow, testable communication rules around those zones. Use the first wave of policy enforcement to prove that containment works without disrupting validated operations.
• Align change control with OT and validation teams Build approval, testing, and rollback steps into every segmentation change so regulated systems can stay compliant while policy evolves. This is especially important where legacy lab equipment or production systems cannot tolerate abrupt network redesign.

Key takeaways

• Pharmaceutical Zero Trust succeeds or fails on containment, not on perimeter replacement.
• Microsegmentation reduces lateral movement by turning broad network trust into identity-based policy enforcement.
• The most durable programmes align security, OT, and application governance before they scale policy across regulated systems.

Key terms

• Microsegmentation: Microsegmentation is the practice of dividing a network or workload estate into small trust zones with tightly scoped communication rules. It reduces lateral movement by enforcing access at the application, workload, or identity level instead of relying on broad subnet trust.
• Zero Trust Maturity Model: A maturity model is a staged way to measure how fully an organisation has adopted a security approach. In this case, the model describes how access governance moves from static controls to dynamic, continuously verified enforcement across identity, device, network, workload, and data domains.
• Blast Radius: Blast radius is the amount of environment an attacker can reach after compromising one asset. In security architecture, it is a practical measure of containment quality, showing whether controls can prevent one foothold from becoming broad operational disruption or data exposure.
• Validated Environment: A validated environment is a regulated system where changes must preserve documented operational and compliance requirements. In pharma, that means security controls like segmentation must be introduced carefully so they do not invalidate production processes, lab workflows, or regulated configurations.

What's in the full article

Elisity's full guide covers the operational detail this post intentionally leaves for the source:

• Assessment questions and scoring criteria for each Zero Trust pillar in pharmaceutical environments
• Implementation considerations for microsegmentation across validated, legacy, and OT-heavy systems
• Business-driver mapping for research collaboration, intellectual property protection, and manufacturing continuity
• Examples of how organisations progressed from initial planning to enforced segmentation policies

👉 The full Elisity article covers microsegmentation readiness, maturity scoring, and implementation guidance for regulated environments.

Deepen your knowledge

The NHI Foundation Level course, the industry's only accredited NHI security programme, covers NHI governance, workload identity, secrets management, and identity lifecycle control. It helps security and identity practitioners connect access governance to broader zero trust and operational resilience programmes.